Pharmaceutical Technology

FEBRUARY 27, 2023

Hydrocortisone is under clinical development by Antares Pharma and currently in Phase I for Adrenal Insufficiency. According to GlobalData, Phase I drugs for Adrenal Insufficiency have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Drug Delivery 100

Drug Delivery Drug Delivery Systems Production Drugs 100

XTalks

JUNE 14, 2023

XTALKS WEBINAR: Drug Delivery — Evaluating Off-The-Shelf and Novel Drug Delivery Solutions Live and On-Demand: Tuesday, July 11, 2023, at 1pm EDT (10am PDT) Register for this free webinar to learn about important tradeoffs when considering an off-the-shelf (OTS) drug delivery platform vs. novel development.

Gene Silencing 97

Gene Silencing Drug Delivery FDA Approval RNA 97

pharmaphorum

MARCH 15, 2022

It’s an example of a fairly uncommon risk-sharing model, in which an investment group funds a clinical development programme in the hope of a bigger payoff down the line, with rights to the drug staying with the pharma partner. Sarclisa has been tipped to become a $1 billion-plus brand, but it still has a long way to go.

Trials 97

Trials Sales Drug Delivery Antibody 97

The Pharma Data

JANUARY 3, 2021

“We are delighted to support our partnership with EyePoint through this investment, as we prepare for the development and commercialization of YUTIQ and DEXYCU, under Ocumension branded labels, across Asian markets,” said Ye Liu, Chief Executive Officer of Ocumension. “We

Production 52

Production Sales Development Licensing 52

The Pharma Data

NOVEMBER 4, 2020

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”).

Licensing 40

Licensing Licensing Dermatology Production 40

The Pharma Data

MAY 15, 2023

8,19 About the Vabysmo® (faricimab) clinical development programme Roche has a robust phase III clinical development programme for Vabysmo. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world.

Antibody 40

Antibody In-Vitro Clinical Development Medicine 40

The Pharma Data

APRIL 12, 2023

1 9 , 20 It develops when new and abnormal blood vessels grow uncontrolled under the macula, causing swelling, bleeding and/or fibrosis. 2 6 About the Vabysmo ® ( faricimab ) clinical development programme Roche has a robust phase III clinical development programme for Vabysmo.

Antibody 40

Antibody In-Vitro Development Trials 40